Pre-formulation investigations for establishing a protocol for treosulfan handling and activation

References

• Abedi-Valugerdi M, Wolfsberger J, Pillai PR, Zheng W, Sadeghi B, Zhao Y, Hassan M. 2016. Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. Int Immunopharmacol. 40:41–49.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA. 2005. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 35:233–241.
   PubMed Web of Science ®Google Scholar
• Chekerov R, Kaltenecker G, Reichert D, Gohler T, Klare P, Oskay-Ozcelik G, Sauer U, Wischnik A, Vehling-Kaiser U, Becker M. 2015. Treosulfan in the treatment of advanced ovarian cancer – results of a German Multicenter Non-interventional Study. Anticancer Res. 35:6869–6875.
   PubMed Web of Science ®Google Scholar
• Danielak D, Twardosz J, Kasprzyk A, Wachowiak J, Kałwak K, Główka F. 2018. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. Eur J Clin Pharmacol. 74:79–89.
   PubMed Web of Science ®Google Scholar
• Duncan ID, Clayton LA. 1985. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan – a phase II study. Br J Obstet Gynaecol. 92:762–767.
   PubMedGoogle Scholar
• Feit PW, Rastrup-Andersen N, Matagne R. 1970. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J Med Chem. 13:1173–1175.
   PubMed Web of Science ®Google Scholar
• Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M, et al. 2007. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res. 27:4021–4025.
   PubMed Web of Science ®Google Scholar
• Glowka F, Kasprzyk A, Romanski M, Wrobel T, Wachowiak J, Szpecht D, Kalwak K, Wiela-Hojenska A, Dziatkiewicz P, Tezyk A. 2015. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT. Eur J Pharm Sci: Off J Eur Federation Pharm Sci. 68:87–93.
   Google Scholar
• Główka FK, Karaźniewicz-Łada M, Grund G, Wróbel T, Wachowiak J. 2008. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 42(Suppl 2):S67–S70.
   PubMed Web of Science ®Google Scholar
• Glowka FK, Lada MK, Grund G, Wachowiak J. 2007. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B: Analyt Technol Biomed Life Sci. 850:569–574.
   PubMed Web of Science ®Google Scholar
• Glowka FK, Romanski M, Tezyk A, Zaba C. 2013. Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers. J Pharm Biomed Anal. 72:145–149.
   PubMed Web of Science ®Google Scholar
• Greystoke B, Bonanomi S, Carr TF, Gharib M, Khalid T, Coussons M, Jagani M, Naik P, Rao K, Goulden N, et al. 2008. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 142:257–262.
   PubMed Web of Science ®Google Scholar
• Gropp M, Meier W, Hepp H. 1998. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol. 71:94–98.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM. 2014. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 20:549–555.
   PubMed Web of Science ®Google Scholar
• Hartley JA, O'Hare CC, Baumgart J. 1999. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 79:264–266.
   PubMed Web of Science ®Google Scholar
• Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, Seeber S, Scheulen ME. 1998. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 42:99–104.
   PubMed Web of Science ®Google Scholar
• Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S, Scheulen ME. 2000. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol. 45:483–488.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, Freund M, Casper J. 2008. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol. 142:284–292.
   PubMed Web of Science ®Google Scholar
• Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM. 2017. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Ann Hematol. 96:479–487.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. 2014. Drug resistance in cancer: an overview. Cancers (Basel). 6:1769–1792.
   PubMed Web of Science ®Google Scholar
• Huang J, Bathena SP, Alnouti Y. 2010. Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer. Drug Metab Pharmacokinet. 25:487–499.
   PubMed Web of Science ®Google Scholar
• Koyyalamudi SR, Kuzhiumparambil U, Nath CE, Byrne JA, Fraser CJ, O'Brien TA, Earl JW, Shaw PJ. 2016. Development and validation of a high pressure liquid chromatography-UV method for the determination of treosulfan and its epoxy metabolites in human plasma and its application in pharmacokinetic studies. J Chromatogr Sci. 54:326–333.
   PubMedGoogle Scholar
• Lin JH, Lu AY. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 35:361–390.
   PubMed Web of Science ®Google Scholar
• Mahner S, Oskay-Ozcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kolbl H. 2012. A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. J Cancer Res Clin Oncol. 138:1413–1419.
   PubMed Web of Science ®Google Scholar
• Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, et al. 1997. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood. 90:4283–4296.
   PubMed Web of Science ®Google Scholar
• Maschan M, Shelikhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, Persiantseva M, Skvortsova Y, Laberko A, Muzalevskii Y, et al. 2016. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant. 51:668–674.
   PubMed Web of Science ®Google Scholar
• Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Na F, Abraham A, Viswabandya A, George B, Mathews V, et al. 2018. Pharmacokinetics and pharmacodynamics of treosulfan in patients with Thalassemia major undergoing allogeneic hematopoietic stem cell transplantation. Clin Pharmacol Therapeut. 104:575–583.
   PubMed Web of Science ®Google Scholar
• Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaaoui RE, Wehner S, Schwabe D, Lehrnbecher T, Schubert R, Kreuter J, et al. 2008. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol. 62:821–830.
   PubMed Web of Science ®Google Scholar
• Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foa R, Milpied N, Peccatori J, Polge E, et al. 2017. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 123:2671–2679.
   PubMed Web of Science ®Google Scholar
• Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, et al. 2011. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 17:341–350.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Remberger M, Torlen J, Serafi IE, Garming-Legert K, Bjorklund A, Ljungman P, Sundin M, Hassan M, Mattsson J. 2017. Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. Int J Hematol. 106:471–475.
   PubMed Web of Science ®Google Scholar
• Romański M, Teżyk A, Zaba C, Główka FK. 2014. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue. Talanta. 127:123–132.
   PubMed Web of Science ®Google Scholar
• Romański M, Urbaniak B, Kokot Z, Główka FK. 2015. Activation of prodrug treosulfan at pH 7.4 and 37 °C accompanied by hydrolysis of its active epoxides: kinetic studies with clinical relevance. J Pharm Sci. 104:4433–4442.
   PubMed Web of Science ®Google Scholar
• Sakellari I, Mallouri D, Gavriilaki E, Batsis I, Kaliou M, Constantinou V, Papalexandri A, Lalayanni C, Vadikolia C, Athanasiadou A. 2017. Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning Regimen in Myelodysplastic Syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplan. 23:445–451.
   PubMedGoogle Scholar
• Sanchez-Garcia I, Martin-Zanca D. 1997. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol. 267:225–228.
   PubMed Web of Science ®Google Scholar
• Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhauser M, Ehninger G, Berdel WE, Baumgart J. 2000. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res: Off J Am Assoc Cancer Res. 6:4209–4216.
   PubMed Web of Science ®Google Scholar
• Schmidmaier R, Oellerich M, Baumgart J, Emmerich B, Meinhardt G. 2004. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol. 32:76–86.
   PubMed Web of Science ®Google Scholar
• Sehouli J, Tome O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chekerov R, Muallem MZ, Lux MP, et al. 2017. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Cancer Res Clin Oncol. 143:541–550.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, et al. 1991. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 16:249–255.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, et al. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 17:1551–1557.
   PubMedGoogle Scholar
• Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, Aschan J, Concha H, Gaughan U, Hassan M. 2006. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 34:115–121.
   PubMed Web of Science ®Google Scholar
• Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S, Nademi Z, Goulden N, Davies G, Qasim W, et al. 2011. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 117:4367–4375.
   PubMed Web of Science ®Google Scholar
• Ten Brink MH, Ackaert O, Zwaveling J, Bredius RG, Smiers FJ, den Hartigh J, Lankester AC, Guchelaar HJ. 2014a. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Ther Drug Monit. 36:465–472.
   PubMed Web of Science ®Google Scholar
• Ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. 2014b. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 19:1572–1586.
   PubMed Web of Science ®Google Scholar
• Wachowiak J, Sykora KW, Cornish J, Chybicka A, Kowalczyk JR, Gorczynska E, Choma M, Grund G, Peters C, Party EPDW. 2011. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 46:1510–1518.
   PubMed Web of Science ®Google Scholar
• van der Stoep M, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, Moes D, Locatelli F, Guchelaar HJ, Zwaveling J, et al. 2017. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 179:772–780.
   PubMed Web of Science ®Google Scholar